FORM PCT/DO/EO/905 (March 2001)

Commissioner for Patents. Box PCT United States Patent and Trademark Office Washington, D.C. 20231

				C.III.CO 300	Washington, D.C. 20231 www.uspto.gov	
U.S. APPLICATION NO.		FIRST HAMED APP	LICANT		ATTY, DOCKET NO.	
09/83	0779	CHIEN	К		6627-PA9025	
				INTERNATIONAL A		
JAMES W MCC BROWN MART 1660 UNION ST SAN DIEGO, C	IN HALLER & 1 FREET	MCCLAIN		PCT/US99/25692 LA FILING DATE PRIORITY DATE 02 NOV 99 02 NOV 98 DATE MAILED: 06 JU		11
NOTIFICAT	TION OF MI	SSING REQUIREMENTS	UNDER 35 U	J.S.C. 371 IN	THE UNITED	
Office as U.S. K Copy Oath Copy Priori Trans	items have been a Designated Basic National Poof the internation of Declaration of Article 19 aminy Document. International Prelication of Annexe	initial application. Translation of finventors(s). Translation of the endments. Other: iminary Examination Report in Engles to the International Preliminary Examination.	to the United Stated Office (37 C Small Entity State of the international of Article 19 amedians and its Annex amination Report	ates Patent and Ti FR 1.495): tus. d application into indments into Eng tes, if any. t into English.	English. lish.	
the indicated items prior to 20 or 30 n U.S.	s in paragraph 3 to months from the p Basic National F		international app	nternational appu lication.	eagon must be med	
acceptance under i la a. Tr. la a. Tr. la b. Pr la c. Oa	as U.S.C. 371: annstation of the a later than the app The current trans. Translation. occassing fee for appropriate 20 o ath or declaration the application (justice and the application of the application	as a _ large entity _ si i must submit the additional claim fe	ng fee will be req priority date. Idicated on the at ication and/or the 37 CFR 1.492(f) h 37 CFR 1.497(cation number an eappropriate 20 c h 37 CFR 1.497(man the appropriate mall entity, includes or cancel the se	uired if submitted tached Notice of Annexes later th a) a) and (b), proper d international fil or 30 months from a) and (b) for the te 20 or 30 month ding any required additional claims	Defective an the ly identifying ing date). A or the priority reasons s from the multiple dependent for which fees are	
ALL OF THE I	TEMS SET FOI	RTH IN 3(a)-3(d), 4 AND 5 ABOV OF THIS NOTICE OR BY 22 OR HE APPLICATION, WHICHEV	E MUST BE SU	BMITTED WIT	THIN TWO (2) 495 applies) FROM	
RESPOND WIL	L RESULT IN	ABANDONMEN 1.				
The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).						
Annexes will be a 7. 1 The Article or 30 (37 CFR 1.	cancelled. A pro e 19 amendments .495(d)) months :	ranstation of the Annexes MUST be occssing fee will be required if subm is are cancelled since a translation was from the priority date.	as not provided b	y the appropriate	20 (37 CFR 1.494(d))	
Applicant is remi address given in	the heading and	mmunication to the United States Painclude the U.S. application no. sho		,		
	A copy of	of this notice MUST be re	turned with	this respons	e.	
Enclosed: P	CT/DO/EO/917 TO-875	☐ Notice of Defective	Translation (Ciuta D. Johnson	Thurste	

Telephone: 703-305-3661

BEST AVAILABLE COPY

Commissioner for Patents, Box PCI United States Patent and Trademark Office Washington, D.C. 2023

			www.us;		
U.S. APPLICATION NO.	FIRST NAMED APPLICA	ATTY. DOCKET NO.			
09/830779	CHIEN .	К	6627-PA9025		
		INTERNA	FIGHAL APPLICATION NO.		
JAMES W MCCLAIN BROWN MARTIN HALLER & MCCLA	IN	PCT	PCT/US99/25692		
1660 UNION STREET SAN DIEGO, CA 92101 2926		I.A. FILING DA	TE PRIORITY DATE		
		02 NOV 9	9 02 NOV 98		
•		DATE MAII	man yurgane		

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements o 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

- (703) 308-4216, for Rules interpretation,
- (703) 308-4212, for CRF submission help,
- (703) 287-0200, for Patentin software help.

Anita D. Johnson

Telephone: 703-305-3661

FORM PCT/DO/EO/920 (March 2001)

WAILABLE COPY